Feng Li is a results-oriented Science & Technology Innovation Director with extensive expertise in molecular diagnostics, oncology research, and precision medicine. They previously served as a Research Fellow at the Cancer Science Institute of Singapore and have held various leadership roles at OrigiMed and HARBOUR BIOMED, where they focused on translational development and business growth. Feng obtained a Ph.D. in Cancer Pharmacology from the National University of Singapore and is committed to driving innovation, mentoring teams, and building strategic partnerships within the scientific community. Currently, Feng continues to lead advancements in science and technology at Danaher Corporation.
This person is not in the org chart
This person is not in any teams
This person is not in any offices